The effect of multiple doses of donepezil HCl on the pharmacokinetic and pharmacodynamic profile of warfarin

British Journal of Clinical Pharmacology, Supplement

Volumn 46, Issue 1, 1998, Pages 45-50

  Tiseo, P J ^a   Foley, K ^b   Friedhoff, L T ^a  

^a EISAI INC   (United States)

^b EISAI CO LTD   (Japan)

Author keywords

Acetylcholinesterase inhibitor; Donepezil; Drug drug interaction; Wafarin

Indexed keywords

DONEPEZIL; PROTHROMBIN; WARFARIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; ELECTROCARDIOGRAM; HEADACHE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; LABORATORY TEST; MALE; NAUSEA; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHARMACODYNAMICS; PRIORITY JOURNAL; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STATISTICAL ANALYSIS; VOMITING;

EID: 0032406257     PISSN: 02643774     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1998.0460s1045.x     Document Type: Article

References (24)

1. 14C). J Label Compounds Radiopharm 1989; XXVII: 835-839.
2. Rogers SL, Yamanishi Y, Yamatsu K. E2020 - the pharmacology of a piperidine cholinesterase inhibitor. In Cholinergic Basis for Alzheimer Therapy, eds Becker R, Giacobini E. Boston: Birkhäuser, 1991: 314-320.
3. Sherman K. Pharmacodynamics of oral E2020 and tacrine in humans: novel approaches. In Cholinergic Basis for Alzheimer Therapy, eds Becker R, Giacobini E. Boston: Birkhäuser, 1991: 321-328.
4. Rogers SL, Friedhoff LT, the Donepezil Study Group. The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US multicenter, randomized, double-blind, placebo-controlled trial. Dementia 1996; 7: 293-303.
5. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT, the Donepezil Study Group. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology 1998; 50: 136-145.
6. Rogers SL, Doody RS, Mohs R, Friedhoff LT, the Donepezil Study Group. Donepezil improves cognition and global function in Alzheimer's disease: a 15-week, double-blind, placebo-controlled study. Arch Intern Med 1998; 158: 1021-1031.
7. Rogers SL, Friedhoff LT. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: an interim analysis of the results of a US multicentre open label extension study. Eur Neuropsychopharmacol 1998; 8: 67-75.
8. Albers GW, Atwood JE, Hirsh J, Sherman DG, Hughes RA, Connolly SJ. Stroke prevention in non-valvular atrial fibrillation. Ann Intern Med 1991; 115: 727-736.
9. Mirsen TR, Hachinski VC. Transient ischemic attacks and stroke. Can Med Assoc J 1988; 138: 1099-1105.
10. Anon. Management of venous thromboembolism. Lancet 1988; i: 275-277.
11. Seller EM, Koch-Weser J. Potentiation of warfarin-induced hypoprothrombinemia by chloral hydrate. N Engl J Med 1970; 283: 827-831.
12. Udal JA. Warfarin-chloral hydrate interaction. Pharmacological activity and clinical significance. Ann Intern Med 1974; 81: 341-344.
13. Fox S. Potentiation of anticoagulants by pyrazole compounds. JAMA 1964; 188: 320-321.
14. Aggeler PM, O'Reilly RA, Leong L, Kowitz PE. Potentiation of anticoagulant effect on warfarin by phenylbutazone. N Engl J Med 1967; 276: 496-501.
15. Majerus P, Broze GJ, Miletich JP, Tollefsen DM. Anticoagulant, thrombolytic and antiplatelet drugs. In Goodman and Gilman's The Pharmacological Basis of Therapeutics, Ninth Edition, eds Gilman AG, Molinoff PB, Ruddon RW, Hardman JG, Limbird LE. New York: McGraw-Hill, 1995: 1341-1359.
16. Tiseo PJ, Rogers SL, Friedhoff LT. Pharmacokinetic and pharmacodynamic profile of donepezil HCl following evening administration. Br J Clin Pharmacol 1998; 46 (Suppl. 1): 13-18.
17. Sansom LN, Evans AM. What is the true clinical significance of plasma protein binding displacement interactions? Drug Saf 1995; 12: 227-233.
18. Rolan PE. Plasma protein binding displacement interactions -why are they still regarded as clinically important? Br J Clin Pharmacol 1994; 37: 125-128.
19. 13C] warfarin pseudoracemates in man. J Clin Invest 1980; 56: 746-753.
20. Banfield C, O'Reilly RA, Chan E, Rowland M. Phenylbutazone-warfarin interaction in man: further stereochemical and metabolic considerations. Br J Clin Pharmacol 1983; 16: 669-675.
21. Day RO, Graham GG, Chapman GD, Lee E. Antirheumatic drug interactions. Clin Rheum Dis 1984; 10: 251-275.
22. Furst DE. Clinically important interactions of non-steroidal antiinflammatory agents with other medications. J Rheumatol 1988; 15 (Suppl. 17): 58-62.
23. Poller L, Hirsh J. Special report: a simple system for the derivation of International Normalized Ratios for the reporting of prothrombin time results with North American thromboplastin reagents. Am J Clin Pathol 1989; 92: 124-126.
24. Kaminsky LS, Dunbar DA, Wang PP. Human hepatic cytochrome P-450 composition as probed by in vitro microsomal metabolism of warfarin. Drug Metab Dispos 1984; 12: 470-477.